Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Articles
BioCentury
|
Jan 28, 2016
Strategy
CIRM's endgame
...not a cause for industry reluctance. He said the company's latest IND, through its subsidiary
Cell Cure Neurosciences Ltd.
...
Read More
BioCentury
|
Oct 19, 2015
Clinical News
OpRegen regulatory update
...early next year. Cell Cure is majority-owned by BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX, Alameda, Calif.).
Cell Cure Neurosciences Ltd.
...
Read More
BioCentury
|
Nov 19, 2012
Company News
BioTime ophthalmic news
...BioTime will purchase 87,456 shares of its
Cell Cure NeuroSciences Ltd.
subsidiary in exchange for 906,735 BioTime shares at...
Read More
BioCentury
|
Oct 25, 2010
Company News
Cell Cure Neurosciences, Teva deal
...therefore eligible to share in milestones received by Cell Cure. Further terms were not disclosed.
Cell Cure Neurosciences Ltd.
...
Read More
BioCentury
|
Jan 29, 2007
Company News
Allon, Amicus Therapeutics, Cell Cure Neurosciences Ltd., Intra-Cellular, Neurocrine, P2D Inc., Proneuron, ReNeuron, Sangamo, Wyeth, Michael J. Fox Foundation F
...Parkinson's disease (PD). Allon Therapeutics Inc . (TSX:NPC), Vancouver, B.C Amicus Therapeutics Inc., Cranbury, N.J.
Cell Cure Neurosciences Ltd.
...
Read More
Items per page:
10
1 - 5 of 5
BioCentury
|
Jan 28, 2016
Strategy
CIRM's endgame
...not a cause for industry reluctance. He said the company's latest IND, through its subsidiary
Cell Cure Neurosciences Ltd.
...
Read More
BioCentury
|
Oct 19, 2015
Clinical News
OpRegen regulatory update
...early next year. Cell Cure is majority-owned by BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX, Alameda, Calif.).
Cell Cure Neurosciences Ltd.
...
Read More
BioCentury
|
Nov 19, 2012
Company News
BioTime ophthalmic news
...BioTime will purchase 87,456 shares of its
Cell Cure NeuroSciences Ltd.
subsidiary in exchange for 906,735 BioTime shares at...
Read More
BioCentury
|
Oct 25, 2010
Company News
Cell Cure Neurosciences, Teva deal
...therefore eligible to share in milestones received by Cell Cure. Further terms were not disclosed.
Cell Cure Neurosciences Ltd.
...
Read More
BioCentury
|
Jan 29, 2007
Company News
Allon, Amicus Therapeutics, Cell Cure Neurosciences Ltd., Intra-Cellular, Neurocrine, P2D Inc., Proneuron, ReNeuron, Sangamo, Wyeth, Michael J. Fox Foundation F
...Parkinson's disease (PD). Allon Therapeutics Inc . (TSX:NPC), Vancouver, B.C Amicus Therapeutics Inc., Cranbury, N.J.
Cell Cure Neurosciences Ltd.
...
Read More
Items per page:
10
1 - 5 of 5
Previous page
Next page